In summary, the apparent lack of robust objective responses reported in patients with breast cancer when receiving antiprogestins has been attributed to the lack of patient stratification according to their molecular profile, in particular the proportion of expression of PR-A relative to PR-B (Lanari et al. 2012, Giulianelli et al. 2013), and the lack of assessment of PR target gene signatures in responders vs non-responders (Hagan & Lange 2014, Knutson & Lange 2014). Here, S100A6 is linked to breast cancer.